Four COVID-19 Vaccine Manufacturers Apply For EUA Registration In Indonesia

JAKARTA - A total of four COVID-19 vaccine manufacturers have submitted the registration process for an Emergency Use Permit (EUA) in Indonesia, said the Head of the Indonesian Food and Drug Administration (BPOM) Penny K Lukito. said Penny K Lukito while attending a working meeting (Raker) with Commission IX of the Indonesian House of Representatives which was monitored virtually from Jakarta, reported by Antara, Wednesday, August 25. Among these producers are Cansino, which was registered by PT Bio Farma for the COVID-19 vaccine with the Recombinant platform. Novel Adenovirus (AD-5) for adults over 18 years. Until now the process is waiting for security data.

The next producer is Johnson and Johnson which is registered by PT Johnson and Johnson Indonesia for an adenovirus platform vaccine with one injection dose in adults over 18 years. The EUA process has now reached the evaluation of the efficacy and safety. Penny said PT Indo Farma registered the Covavax vaccine with a recombinant protein sub unit platform for adults over 18 years old. Currently waiting for the clinical trial phase in India to be completed. The last producer is PT Amarox which registers the Covaxin vaccine with the Inactivated virus platform or the virus is turned off for adults over 18 years old. Currently, the process is waiting for additional efficacy and safety data. If all stages of the process are successfully achieved by producers, said Penny, then the four vaccine candidates will add variants of the COVID-19 vaccine that have already obtained EUA in Indonesia, including Coronavac, Bio Farma vaccine, AstraZeneca , Sinopharm, Moderna, Pfizer (Cominaty), and Sputnik-V.